Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Self-citationType 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
“239,240 The effect of hypoglycemic agents on body weight should be considered, and it is reasonable to use drugs with weight-loss effect in T2D patients with preobesity/obesity as an adjunct to lifestyle interventions.”
BackgroundCardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention
Wong, N. D., & Sattar, N. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00877-z · Cited by 495
Genitsaridi, I., Salpea, P., Salim, A., Sajjadi, S. F., Tomic, D., James, S., Thirunavukkarasu, S., Issaka, A., Chen, L., Basit, A., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00299-2 · Cited by 501
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s005 · Cited by 362
Self-citationNeuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067584 · Cited by 358
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“…with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as fi rst-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal bene fi ts [109].”
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“Several GLP-1 RAs are approved for the treatment of T2DM and obesity and have the additional benefit of reducing major cardiovascular and renal events in those with T2DM and established cardiovascular disease 268,269 .”
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“, the secretion of insulin in response to oral glucose ingestion mediated by GLP-1 and glucose-dependent insulinotropic peptide—GIP) in patients with T2DM and the significant anti-hyperglycemic action, GLP-1 RAs are strongly recommended in the management of patients with T2DM [13].”
BackgroundInfluentialAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Beverly, E. A., Bruemmer, D., Collins, B. S., Darville, A., Ekhlaspour, L., Hassanein, M., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s005 · Cited by 285
Self-citationMetformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 248
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Self-citationCurrent insights and emerging trends in early-onset type 2 diabetes
Misra, S., Ke, C., Srinivasan, S., Goyal, A., Nyriyenda, M. J., Florez, J. C., Khunti, K., Magliano, D. J., & Luk, A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00225-5 · Cited by 222
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Self-citationElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 222
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Kelly, T., Irvine, K., Peters, C., Zhyzhneuskaya, S., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00385-6 · Cited by 186
Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071689 · Cited by 168
“18 Although SGLT2 inhibitors are strongly guideline-recommended to reduce the risk of heart failure outcomes in people with diabetes, CKD, or heart failure, 5,19,20 the effect of GLP-1 receptor agonists on this outcome has been less clear.”
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 165
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Rosenstock, J., Bain, S. C., Gowda, A., Jódar, E., Liang, B., Lingvay, I., Nishida, T., Trevisan, R., & Mosenzon, O. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303208 · Cited by 163
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 252
Self-citationLam, T.-P., Tran, N.-V. N., Pham, L.-H. D., Lai, N. V.-T., Dang, B.-T. N., Truong, N.-L. N., Nguyen-Vo, S.-K., Hoang, T.-L., Mai, T. T., & Tran, T. (2024) · Natural Products and Bioprospecting · doi:10.1007/s13659-023-00424-w · Cited by 232
“…available anti-diabetic therapeutics include sulfonylureas, meglitinides, thiazo-lidinediones, biguanides, dipeptidyl peptidase-IV inhibitors (DPP-4i), glucagon-like-peptide-1 receptor agonist (GLP1-RA), sodium-glucose transporter-2 inhibitors (SGLT-2i), and α-glucosidase inhibitors [4, 5].”
BackgroundDiagnosis and Treatment of Type 2 Diabetes in Adults: A Review
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 204
Self-citation3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s003 · Cited by 144
Lingvay, I., Asong, M., Desouza, C. V., Gourdy, P., Kar, S., Vianna, A. G. D., Vilsbøll, T., VINTHER, S. M., & Mu, Y. (2023) · JAMA · doi:10.1001/jama.2023.11313 · Cited by 153
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
McGuire, D. K., Busui, R. P., Deanfield, J., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N., Engelmann, M. D. M., Hovingh, G. K., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15058 · Cited by 131
“Cardiovascular (CV) disease (CVD) is a common cause of morbidity and mortality in individuals with type 2 diabetes.(1,2) People with type 2 diabetes have a higher risk of coronary artery disease (CAD), heart failure (HF), stroke, peripheral arterial disease (PAD) and atrial fibrillation when compared to those without…”
BackgroundSelf-citationDawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00340-0 · Cited by 131
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Self-citationCombination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
“…Diabetes Association and the European Association for the Study of Diabetes recommended use of SGLT2 inhibitors for patients with T2DM and CKD, preferably in combination with GLP1R agonists if further glucose control is needed, because of the CVD benefit of these agonists in this population 132 .”
Self-citationGourdy, P., Darmon, P., Dievart, F., Halimi, J.-M., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 127
“In respect to their cardiovascular effects among patients with T2DM, both GLP-1RAs and SGLT2is have been shown to reduce the risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke), with GLP-1RAs reducing the risk of non-fatal stroke to a greater extent [3, 6].”
BackgroundMethodResultInfluentialAroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Self-citationPrecision subclassification of type 2 diabetes: a systematic review
Misra, S., Wagner, R. J., Özkan, B., Schön, M., Sevilla-González, M. D. R., Prystupa, K., Wang, C. C., Kreienkamp, R. J., CROMER, S. J., Rooney, M. R., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00360-3 · Cited by 148
“…glucose-lowering therapies on the basis of higher body mass index (BMI) (favouring use of glucagon-like peptide analogue, GLP-1) or presence or absence of cardiovascular and/or renal disease and/or heart failure (favouring GLP-1 and/or sodium-glucose co-transporter 2, SGLT-2 inhibitors) 3 .”
BackgroundDiabetes and Multiple Long-term Conditions: A Review of Our Current Global Health Challenge
Khunti, K., Chudasama, Y., Gregg, E. W., Kamkuemah, M., Misra, S., Suls, J. M., Venkateshmurthy, N. S., & Valabhji, J. (2023) · Diabetes Care · doi:10.2337/dci23-0035 · Cited by 158
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
“Considering the many advantages mentioned herein, SGLT-2i are recommended as a first-line therapy for T2DM with CVD or renal disease by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [21].”
BackgroundInfluentialCastañeda, J., Arrieta, A., van den Heuvel, T., Battelino, T., & Cohen, O. (2024) · Diabetes Care · doi:10.2337/dc23-1581 · Cited by 107
Artificial intelligence for diabetes care: current and future prospects
Sheng, B., Pushpanathan, K., Guan, Z., Lim, Q. H., Lim, Z. W., Yew, S. M. E., Goh, J. H. L., Bee, Y. M., Sabanayagam, C., Sevdalis, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00154-2 · Cited by 106
Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L. (2023) · Nature Medicine · doi:10.1038/s41591-023-02344-1 · Cited by 104
Ray, K. K., Nicholls, S. J., Li, N., Louie, M. J., Brennan, D., Lincoff, A. M., & Nissen, S. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00316-9 · Cited by 99
Mauricio, D., Gratacòs, M., & Franch‐Nadal, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02056-3 · Cited by 132
“Intensive blood glucose control has been shown to effectively prevent the onset or delay the progression of diabetic microvascular complications, while its effect is modest or even neutral on the prevention of macrovascular disease [5].”
BackgroundThe role of structural racism and geographical inequity in diabetes outcomes
Agarwal, S., Wade, A. N., Mbanya, J. C., Yajnik, C., Thomas, N., Egede, L. E., Campbell, J. A., Walker, R. J., Maple-Brown, L., & Graham, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00909-1 · Cited by 97
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s005 · Cited by 277
Self-citationCardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Yabe, D., Shiki, K., Homma, G., Meinicke, T. W., Ogura, Y., Seino, Y., & EMPA‐ELDERLY Investigators (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15249 · Cited by 110
Mesinovic, J., Fyfe, J. J., Talevski, J., Wheeler, M. J., Leung, G. K. W., George, E. S., Hunegnaw, M. T., Glavas, C., Jansons, P., Daly, R. M., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0112 · Cited by 114
“Regular physical activity is recommended for management of glucose control in older adults with T2DM [125,126].”
BackgroundZhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · BMC Medicine · doi:10.1186/s12916-024-03274-6 · Cited by 82
Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
“2,21 Cohort entry was de fi ned as the date of dispensing of a fi rst prescription of either GLP1-RA or DPP-4i, with follow-up beginning 1 year after cohort entry to allow for a latency time window and to reduce reverse causality and detection bias.”
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 93
“For patients with T2D, ADA/European Association for the Study of Diabetes guidelines recommend the use of basal insu-lins with the lowest propensity to cause hypoglycemia (17, 168).”
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
RYKOVA, E. Y., Klimontov, V. V., Shmakova, E. O., Korbut, A. I., Merkulova, T. I., & Kzhyshkowska, J. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041670 · Cited by 100
“The modern diabetes management strategy involves individualization of treatment taking into account the range of complications and associated diseases [4].”
Robinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73
Lind, N., Christensen, M. B., Hansen, D. L., & Nørgaard, K. (2024) · Diabetes Care · doi:10.2337/dc23-2194 · Cited by 71
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves, J. S., Borges-Canha, M., Vasques-Nóvoa, F., Green, J. B., Leiter, L. A., Granger, C. B., Carvalho, D., Leite-Moreira, A., Hernandez, A. F., Del Prato, S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.048 · Cited by 71
Self-citationPan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 71
“The use of medications such as liraglutide, semaglutide, and tirze-patide is aligned with the 2022 guidance of the American Diabetes Association and the European Association for the Study of Diabetes, which has made weight loss a priority in patients with T2DM [78].”
BackgroundSattar, N., Presslie, C., Rutter, M. K., & McGuire, D. K. (2024) · Diabetes Care · doi:10.2337/dci23-0041 · Cited by 70
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
“Pioglitazone, a TZD derivative, is a peroxisome proliferator – activated receptor (PPAR) g agonist used for the treatment of type 2 diabetes (24).”
MethodWaking Up to the Importance of Sleep in Type 2 Diabetes Management: A Narrative Review.
Henson, J., Covenant, A., Hall, A. P., Herring, L., Rowlands, A. V., Yates, T., & Davies, M. J. (2024) · Diabetes Care · doi:10.2337/dci23-0037 · Cited by 69
Self-citationShields, B. M., Dennis, J., Angwin, C. D., Warren, F. C., Henley, W., Farmer, A. A., Sattar, N. A., Holman, R. R., Jones, A. G., Pearson, E. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02120-7 · Cited by 76
“In patients with established atherosclerotic cardiovascular disease, glucagon-like peptide 1 receptor agonists (GLP-1RA) or sodium–glucose co-transporter 2 inhibitors (SGLT2i) are recommended 5 .”
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
“…glycemic control in patients with T2D and as a first-line therapy in established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to reduce the risk of major adverse cardiovascular events (MACE), i.e., myocardial infarction, stroke and cardiovascular death [5,6].”
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
“19,20 It is plausible that GLP-1 RA also reduce the incidence of obesity-associated cancers, as recently suggested by an observational study 21 ; on the other hand, another investigation failed to detect any effect of these drugs on the incidence of cancer.”
Mark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 90
“The recommendation is that the therapy should be based on assessment of established ASCVD, CKD or HF with goals of glycaemic control and cardiorenal protection considered in partnership [ 69 ].”
MethodHuber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“The American Diabetes Association and the European Association for the Study of Diabetes also highlight the importance of body weight management through diet and physical exercise which play an integral role in a holistic approach to T2DM management [90].”
BackgroundRogers, E. M., Banks, N. F., & Jenkins, N. D. M. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3667 · Cited by 62
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
Wysham, C., BAJAJ, H. S., Prato, S. D., Franco, D. R., Kiyosue, A., Dahl, D. B., Zhou, C., Carr, M. C., Case, M. G., & GONCALVES, L. F. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403953 · Cited by 73
Self-citationMailhac, A., Pedersen, L., Pottegård, A., Søndergaard, J., Mogensen, T., Sørensen, H., & Thomsen, R. (2024) · Clinical Epidemiology · doi:10.2147/clep.s456170 · Cited by 60
“3,22 Since 2015, numerous large cardiovascular outcome trials have shown that GLP-1RAs including semaglutide reduce cardiovascular and renal complications in high-risk T2D patients and confer organ-protective effects beyond lowering glucose.”
BackgroundPereira, L., & Valado, A. (2023) · Life · doi:10.3390/life13091831 · Cited by 76
“While advancements have been made in conventional diabetes management, there is a growing interest in exploring alternative therapeutic strategies that offer improved efficacy, fewer side effects, and disease-modifying potential [11,12].”
Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
Klonoff, D. C., Kim, S. H., Galindo, R. J., Joseph, J. I., Garrett, V., Gombar, S., Aaron, R. E., Tian, T., & Kerr, D. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15636 · Cited by 58
Zikou, E., Dovrolis, N., Dimosthenopoulos, C., Gazouli, M., & Makrilakis, K. (2023) · Nutrients · doi:10.3390/nu15214663 · Cited by 71
Kwon, O., Myong, J., Lee, Y., Choi, Y.-J., Yi, J. E., Seo, S. M., Jang, S.-W., Kim, P. J., & Lee, J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027824 · Cited by 60
Ruggiero, R., Mascolo, A., Spezzaferri, A., Carpentieri, C., Torella, D., Sportiello, L., Rossi, F., Paolisso, G., & Capuano, A. (2024) · Pharmaceuticals · doi:10.3390/ph17020147 · Cited by 55
Changes in the use of glucose‐lowering drugs: A Danish nationwide study
Pottegård, A., Andersen, J. H., Søndergaard, J., Thomsen, R. W., & Vilsbøll, T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14947 · Cited by 54
“In addition to their effective glucose-lowering properties, these drugs have a very low risk of hypoglycaemia.(8) Furthermore, since 2015, results from large cardiovascular outcomes trials have proven that GLP-1RAs and SGLT-2is provide cardiorenal benefits in people with type 2 diabetes and high cardiovascular risk in…”
BackgroundLegaard, G. E., Lyngbæk, M. P. P., Almdal, T., Karstoft, K., Bennetsen, S. L., Feineis, C. S., Nielsen, N. S., Durrer, C. G., Liebetrau, B., Nystrup, U., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00799-7 · Cited by 66
“Intensive structured weight management programs aiming for weight loss are recommended alongside pharmacological therapy to treat hyperglycemia 17 .”
BackgroundLiu, Y., Lin, S., Xu, Z., Wu, Y., Wang, G., Yang, G., Cao, L., Chang, H., Zhou, M., & Jiang, X. (2024) · Advanced Science · doi:10.1002/advs.202309491 · Cited by 75
Bercea, M., & Lupu, A. (2024) · Gels · doi:10.3390/gels10040260 · Cited by 65
Inverse Association between Oxidative Balance Score and Incident Type 2 Diabetes Mellitus
Kwon, Y., Park, H.-M., & Lee, J. (2023) · Nutrients · doi:10.3390/nu15112497 · Cited by 52
“Therefore, research groups have provided evidence that adopting a healthy lifestyle, encompassing reduced alcohol consumption, weight control, and increased vegetable intake, can effectively mitigate the risk of developing T2DM among individuals with impaired glucose tolerance and fasting glucose levels [32].”
BackgroundBajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 137
Self-citationMałecki, M. T., Batterham, R. L., Sattar, N., Levine, J. A., Rodríguez, Á., Bergman, B. K., Wang, H., Ghimpeteanu, G., & Lee, C. J. (2023) · Diabetes Care · doi:10.2337/dc23-1135 · Cited by 52
Dennis, J., Young, K. G., Cardoso, P., Güdemann, L. M., McGovern, A. P., Farmer, A. A., Holman, R. R., Sattar, N. A., McKinley, T. J., Pearson, E. R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02617-5 · Cited by 65
“…Oct 14, 2020, excluding initiations in which individuals received the medication as first-line glucose-lowering therapy (as this is not recommended in current treatment guidelines 4 ), those with concurrent treatment with insulin, or those with a pre-existing diagnosis of end-stage kidney disease.”
Prevalence, Cost, and Burden of Diabetic Ketoacidosis
Virdi, N. S., Poon, Y., Abaniel, R. M., & Bergenstal, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0149 · Cited by 68
Neuen, B. L., Tuttle, K. R., & Vaduganathan, M. (2024) · Circulation · doi:10.1161/circulationaha.123.068524 · Cited by 53
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management
Espósito, D., Boguszewski, C. L., Colao, A. A. L., Fleseriu, M., Gatto, F., Jørgensen, J. O. L., Ragnarsson, Ó., Ferone, D., & Johannsson, G. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00993-x · Cited by 72
Zhang, Y., Yin, X., Liu, T., Ji, W., & Wang, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-71778-5 · Cited by 59
“Current strategies include maintaining blood glucose levels within a specific target range using insulin therapy, with a preference for intravenous administration due to its adjustability 30 .”
Minimally and non-invasive glucose monitoring: the road toward commercialization
Min, S. Q., Geng, H., He, Y., Xu, T., Liu, Q., & Zhang, X. (2025) · Sensors & Diagnostics · doi:10.1039/d4sd00360h · Cited by 65
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Mazzieri, A., Porcellati, F., Timio, F., & Reboldi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073969 · Cited by 64
“Major guidelines already recommend a multi-agent strategy, personalized to the individual residual renal and/or cardiorenal risk [12,13].”
BackgroundMichalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 76
“…mellitus (T2DM) patients from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) are now focusing more on tailoring treatment strategies to each individual, especially for patients with coexisting cardiovascular or liver-related conditions [153].”
Fuentes-Barría, H., Aguilera-Eguía, R. A., Flores-Fernández, C., Angarita, L., Rojas-Gómez, D. M., Alarcón-Rivera, M., López-Soto, O., & Maureira-Sánchez, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052153 · Cited by 245
“Therefore, its guidelines only apply to individuals with vitamin D deficiency or those at risk, such as older adults, pregnant women, or individuals on restrictive diets, whose needs may require supplementation [3,33,37,38].”
Tirzepatide: A Review in Type 2 Diabetes
France, N. L., & Syed, Y. Y. (2024) · Drugs · doi:10.1007/s40265-023-01992-4 · Cited by 51
“US and EU treatment guidelines recommend a holistic person-centred approach to T2DM management, with the goals being to prevent complications and optimize quality of life [2, 41, 42].”
InfluentialZhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4162 · Cited by 49
Caruso, I., & Giorgino, F. (2024) · Endocrine · doi:10.1007/s12020-024-03757-9 · Cited by 60
“…consensus, the European Association for the Study of Diabetes and the American Diabetes Association recommended pursuing a 5 – 15% weight loss as a primary target of management [71], highlighting that losing 10 – 15% of BW could have disease-modifying effects spreading beyond glucose control [72].”
BackgroundBidulka, P., Lugo-Palacios, D. G., Carroll, O., O’Neill, S., Adler, A., Basu, A., Silverwood, R. J., Bartlett, J. W., Nitsch, D., Charlton, P., et al. (2024) · BMJ · doi:10.1136/bmj-2023-077097 · Cited by 63
Managing early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Therapeutic Inertia in the Management of Type 2 Diabetes: A Narrative Review
Rodriguez, P., Martin, V. T. S., & Pantalone, K. M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01530-9 · Cited by 67
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin, J., Xu, Y., Chang, A. R., Carrero, J. J., Flaherty, C. M., Mukhopadhyay, A., Inker, L. A., Blecker, S., Horwitz, L. I., & Grams, M. E. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.057 · Cited by 67
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.